<DOC>
	<DOCNO>NCT02874586</DOCNO>
	<brief_summary>An open-label , pilot study evaluate efficacy safety plasma exchange combination immunosuppressive regimen , remission autoimmune hepatitis ( AIH ) .</brief_summary>
	<brief_title>Plasma Exchange Combination Immunosuppressive Regimens Auto-immune Hepatitis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Autoimmune</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Diagnosed autoimmune hepatitis base liver biopsy result , indication immunosuppressive therapy ; High level total bilirubin ( TB ) ( ≥10 X ULN ) ; High level immunoglobulin G ( IgG ) ( ≥1.5 X ULN ) ; Agreed participate trial , assign informed consent ; The presence hepatitis A , B , C , D , E virus infection ; Patients presence liver cirrhosis portal hypertension ; Primary sclerosing cholangitis , nonalcoholic steatohepatitis , drug induce liver disease Wilson disease confirm liver biopsy ; Pregnant breed woman ; Patients severe anemia ( hemoglobin &lt; 8 g/dL ) , leukopenia ( WBC &lt; 2500/mm3 ) , thrombocytopenia ( platelet count &lt; 50,000/mm3 ) ; Severe disorder vital organ , severe heart failure , cancer ; Parenteral administration blood blood product within 6 month screen ; Recent treatment drug know liver toxicity ; Taken part clinic trial within 6 month screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>